Skip to main content
ABBV logo

AbbVie Inc. (ABBV) Stock: Price, Forecast & Analyst Target

AbbVie Inc. (ABBV) — MoonshotScore 81/100 (Exceptional band), calculated Nov 16, 2026. Price $294.67 (-0.12%), as of the Nov 16, 2026 trading session; market cap $521B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 48.36× (market value Nov 16, 2026; cash Sep 30, 2026) · expected results Feb 3, 2027

$294.67 −$0.36 (-0.12%) Market Cap $521B

AbbVie Inc. · ABBV · NYSE · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): AbbVie sells prescription medicines across immunology, oncology, neuroscience, eye care and other therapeutic markets, with Skyrizi and Rinvoq now far more important to revenue than Humira. The decisive issue is whether those growing immunology franchises can sustain rising sales and cash generation while AbbVie carries substantial debt and funds a broad research portfolio.

Price as of Nov 16, 2026

Key Statistics

81 of 100

MoonshotScore v2 · AbbVie (ABBV)

Exceptional
Business Quality Elite (83)
Financial Safety Sound (74)
Valuation Full (50)
Growth Durability Growing (61)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • quarterly revenue $17.40B (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 7 of the last 8 reports
  • expected results Feb 3, 2027

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ABBV (54 recorded, newest six shown)
RecordedScoreBand
82Exceptional
82Exceptional
81Exceptional
81Exceptional
81Exceptional
81Exceptional

The score moved from 82 in the stored Nov 15, 2026 snapshot to 81 in the current publication computed Nov 16, 2026 (-1); the largest pillar moves were Valuation -2 and Momentum -2.

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$294.672.7% below its all-time high of $302.93 ()
Change on the day-0.12%
52-week range$190.75–$302.93
Market capitalisation$521B
Price / earnings (trailing)50.44
Shares traded on the day4.69M
Beta (volatility vs the S&P 500)0.28
Dividends per share (last 12 months)$6.92
Dividend yield (last 12 months)2.35%

Why AbbVie scores 81

Dr. Mira Sol, the Stock Expert AI TV data character
Momentum carries the score; Valuation is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
81Exceptional
  • Business Quality83
  • Financial Safety74
  • Valuation50
  • Growth Durability61
  • Momentum89

Share price, last 12 months +34.1%

$218.71 $293.30

What the price assumes

11.5% a year of free-cash-flow growth for ten years is what a $521.00B market value () asks for.

  • Price implies, next ten years11.5%
  • Free cash flow, last 5 years1.2%
  • Revenue, last 5 years6.0%
  • Analysts' revenue path, 2026–20306.2%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $18.87B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 4.9% either way.

  1. +2.2%Feb ’24
  2. -3.4%Apr ’24
  3. +5.1%Jul ’24
  4. +7.6%Oct ’24
  5. +8.2%Jan ’25
  6. +6.6%Apr ’25
  7. +3.1%Jul ’25
  8. -7.1%Oct ’25
  9. -2.9%Feb ’26
  10. +6.9%Apr ’26
  11. -4.8%Jul ’26
  12. -0.7%Oct ’26
Next-session move EPS beat (11) EPS miss (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatIn line-0.7%+0.2%
BeatBeat-4.8%-4.4%
BeatBeat+6.9%+3.7%
BeatBeat-2.9%-2.1%
BeatBeat-7.1%-4.0%
BeatBeat+3.1%+5.0%
BeatBeat+6.6%+10.0%
MissBeat+8.2%+8.5%
BeatBeat+7.6%+6.2%
BeatBeat+5.1%+7.7%
BeatBeat-3.4%-2.1%
BeatBeat+2.2%+3.9%

Beating the estimate has not been enough: the stock fell after 5 of the last 11 beats. The bar it has to clear is the whisper number, not the published one.

Our track record on this stock

Since the score went from 82 to 81 while the share price moved +11.4% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range
Band changes, newest first. “Right” means the price moved the way the change pointed over the next three months.
DateBand3 months6 monthsCall
Strong → Exceptional———
Exceptional → Strong———
Strong → Exceptional———
Exceptional → Strong———
Strong → Exceptional———
Exceptional → Strong———

None of the 6 band changes we have recorded has been graded yet; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 70% of 44 rate it a buy; the average target sits +4.8% from the price of $294.67.
  • Last 90 days: 1 upgrade and 0 downgrades among 21 rating actions.
  • Our signals: Exceptional band; strongest pillar Momentum (89), weakest Valuation (50).

Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 16, 2026: low $199, high $295, latest $295. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $295 $199 high $295 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $2231Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $2072Jul 31, 2026 · Earnings results · reported above the recorded estimate · close $2513Oct 30, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $2954Oct 30, 2026 · Earnings results · reported above the recorded estimate · close $2955 Oct 17, 2025 Nov 16, 2026 · $295 $230Oct 17, 2025$218Oct 31, 2025$232Nov 14, 2025$228Nov 28, 2025$223Dec 12, 2025$230Dec 26, 2025$220Jan 9, 2026$219Jan 23, 2026$223Feb 6, 2026$225Feb 20, 2026$230Mar 6, 2026$205Mar 20, 2026$209Apr 2, 2026$208Apr 17, 2026$207May 1, 2026$210May 15, 2026$218May 29, 2026$228Jun 12, 2026$253Jun 26, 2026$248Jul 10, 2026$259Jul 24, 2026$246Aug 7, 2026$265Aug 21, 2026$256Sep 4, 2026$264Sep 18, 2026$263Oct 2, 2026$285Oct 16, 2026$295Oct 30, 2026$295Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleJan 15, 2027, Ex-dividend date; Feb 3, 2027, Next results due; Feb 16, 2027, Dividend payment date. Spacing is order only and carries no duration.Nov 16, 20261Jan 15, 20272Feb 3, 20273Feb 16, 2027
  1. Ex-dividend dateCompany record
  2. Next results dueProvider estimate
  3. Dividend payment dateCompany record

Management outlook

  • We continue to forecast full year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.8 billion and adjusted SG&A expense of approximately $14.5 billion.

    Scott Reents · Statement from

  • We also anticipate an adjusted operating margin of approximately 46.7% of sales, which includes a roughly 1.8% unfavorable impact from acquired IPR&D expense incurred through the third quarter.

    Scott Reents · Statement from

How to read these dates

Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for AbbVie (ABBV): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Overvalued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Nov 17, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 17, 2026, except a card that shows its own read date.

1 · What is it?

What is AbbVie (ABBV), and what does it report?

Short answer · as of

AbbVie is not simply a diversified drug manufacturer: its economics are increasingly anchored by Skyrizi and Rinvoq, while Humira has become a smaller part of the reported product mix. Therapeutic Botox, Vraylar and medicines spanning cancer, migraine, eye care and digestive disease add breadth, but immunology remains the largest visible revenue engine.

Reported revenue measures product sales across this portfolio, whereas reported profit also reflects heavy research and selling costs. Those expenses can make earnings much more volatile than demand for the medicines themselves.

2 · Latest results

What do the latest results show for AbbVie (ABBV)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $17.40B.

The latest period showed a strong sequential rise in revenue, operating profit, net income and diluted earnings. Revenue and adjusted earnings also exceeded consensus expectations, extending a run of company-level sales beats.

The current product mix points to Skyrizi and Rinvoq as the commercial mechanism behind AbbVie's transition away from Humira dependence, but the available quarterly results do not assign the latest change to individual medicines. Research spending remained substantial, so the profit recovery reflects revenue growth and improved operating absorption alongside continued pipeline investment, not a retreat from development activity.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$17.40B Sep 30, 2026
Latest quarter · R&D
$2.78B Sep 30, 2026
Latest quarter · SG&A
$4.09B Sep 30, 2026
Latest quarter · FMP standardized operating result
$6.27B Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$17.40B$2.78B$4.09B$6.27B
Jun 30, 2026$16.99B$2.34B$3.63B$6.43B
Mar 31, 2026$15.00B$2.47B$3.58B$3.99B
Dec 31, 2025$16.62B$2.58B$3.90B$4.54B
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$17.40B Oct 30, 2026
Latest report · revenue estimate
$17.32B Oct 30, 2026
Latest report · revenue vs estimate
Above estimate Oct 30, 2026
Latest report · EPS vs estimate
Above estimate Oct 30, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 30, 2026$17.40B$17.32B$3.8200$3.7300
Jul 31, 2026$16.99B$16.80B$3.6500$3.6100
Apr 29, 2026$15.00B$14.72B$2.6500$2.5900
Feb 4, 2026$16.62B$16.41B$2.7100$2.6500
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$17.40B$4.22B$2.38 (diluted)
Q2 FY2026$16.99B$3.61B$2.04 (diluted)
Q1 FY2026$15.00B$695M$0.39 (diluted)
Q4 FY2025$16.62B$1.82B$1.02 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for AbbVie (ABBV)?

Short answer

Cash and short-term investments were $10.77B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $7.61B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

AbbVie consistently produces positive operating cash flow, and capital spending is modest relative to that inflow. Cash has moved unevenly and ended below its opening level across the reported window, yet cash generation remained resilient even when accounting earnings weakened.

Debt substantially exceeds cash and investments, while short-term liquidity ratios sit below full coverage. Strong gross and operating profitability help support that capital structure, but any sustained erosion in Skyrizi or Rinvoq sales, or another sharp rise in research costs without corresponding commercial output, would reduce the cushion. The quality screen is strong, while the distress screen offers a less emphatic signal.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$7.61B Sep 30, 2026
Previous quarter · operating cash flow
$3.44B Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$7.61B−$301.00M
Jun 30, 2026$3.44B−$322.00M
Mar 31, 2026$3.83B−$265.00M
Dec 31, 2025$5.22B−$329.00M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at AbbVie (ABBV)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

The next earnings report should show whether revenue can continue advancing while operating profit and cash generation hold their recent recovery. The most useful confirmation would be continued commercial strength from Skyrizi and Rinvoq without renewed compression from research and selling costs.

Consensus expects revenue and earnings to expand over the coming years, and recent results have generally cleared expectations. That raises the execution bar: watch the reported product mix, operating margin, cash balance and debt together rather than treating an earnings beat as sufficient evidence on its own.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. And we expect to deliver top-tier growth again next year.

    Robert Michael ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does AbbVie compare with its peers?

Short answer

AbbVie's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

AbbVie's distinguishing feature is the combination of large immunology franchises with a broad set of established specialty medicines, including therapeutic Botox, Vraylar and oncology treatments. That makes it less dependent on a lone experimental pipeline than a narrow biotechnology company, yet more concentrated in Skyrizi and Rinvoq than the breadth of its therapeutic list might suggest.

Its cash profile also differs from that of a development-stage drug maker: operations already generate substantial cash, while the main financial constraint is leverage rather than recurring cash burn. The comparison that matters is therefore commercial durability under a heavy debt load, not simply the breadth of the pipeline.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1434.26 Nov 16, 2026$1.35T98 5-pillar Nov 16, 2026
Sanofi (SNY) Same industry, near in market value$48.39 Nov 16, 2026$116B91 5-pillar Nov 16, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$62.93 Nov 16, 2026$129B90 5-pillar Nov 16, 2026
AstraZeneca PLC (AZN) Same industry, near in market value$184.02 Nov 16, 2026$285B87 5-pillar Nov 16, 2026
Novartis AG (NVS) Named competitor$160.20 Nov 16, 2026$303B86 5-pillar Nov 16, 2026
Novo Nordisk A/S (NVO) Named competitor$41.60 Nov 16, 2026$183B86 5-pillar Nov 16, 2026
Amgen Inc. (AMGN) Same industry, near in market value$462.32 Nov 16, 2026$250B86 5-pillar Nov 16, 2026
Johnson & Johnson (JNJ) Named competitor$282.55 Nov 16, 2026$680B84 5-pillar Nov 16, 2026
GSK plc (GSK) Same industry, near in market value$50.41 Nov 16, 2026$101B84 5-pillar Nov 16, 2026
AbbVie (ABBV) — this page$294.67$521B81
UnitedHealth Group Incorporated (UNH) Named competitor$412.02 Nov 16, 2026$369B75 5-pillar Nov 16, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$167.58 Nov 16, 2026$208B74 5-pillar Nov 16, 2026
Merck & Co., Inc. (MRK) Named competitor$144.46 Nov 16, 2026$356B72 5-pillar Nov 16, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$275.00 – $340.00
Consensus target
$313.80
Median target
$315.00

Consensus record · Captured .

Measured against a quoted price of $294.67 (as of Nov 16, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
13
Identified insiders
4
Purchases
0
Sales
2
Other transactions
11

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
60.9% Period end Sep 30, 2026
Previous quarter · ownership
76.1% Prior to period end Sep 30, 2026
Reporting holders
3,893 Period end Sep 30, 2026
Previous quarter · holders
4,369 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.148,974,939
Vanguard Capital Management LLC115,676,728
State Street Corp82,815,387
Vanguard Portfolio Management LLC49,001,331
Geode Capital Management, LLC47,503,777

Tracked investors

Which of the 16 named investors we follow held ABBV in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260%$0Sold out (was $2.96M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about AbbVie (ABBV)?

Read these with our analysis →

What Investors Ask About AbbVie (ABBV) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How dependent is AbbVie on Skyrizi and Rinvoq?

Skyrizi is AbbVie's largest reported product franchise, and Rinvoq is also materially larger than Humira in the current mix. Their combined durability is therefore central to revenue growth and to the success of AbbVie's transition away from Humira dependence.

What does Humira's smaller role mean for AbbVie?

Humira is no longer the dominant product in the reported mix; Skyrizi and Rinvoq have moved ahead of it. AbbVie's results now depend more on sustaining those successor franchises than on preserving Humira's former scale.

Why can AbbVie's research spending make earnings volatile?

Research expense has varied sharply across reported periods, and the elevated period coincided with an operating loss even though operating cash flow stayed positive. That separation means reported earnings can swing more dramatically than the underlying cash inflow.

Can Skyrizi-led cash generation support AbbVie's debt load?

Operating cash flow is substantial and persistent, but debt remains far larger than cash and investments. Support for the balance sheet therefore depends on continued portfolio cash generation, especially from Skyrizi and Rinvoq, rather than cash reserves alone.

What is the ABBV stock price today?

The last price recorded for AbbVie Inc. (ABBV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ABBV price target?

The analyst consensus price target for AbbVie Inc. (ABBV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.

Sources: the source register lists the 83 figures on this page — 2 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 2 with no recorded source, 5 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is AbbVie (ABBV), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for AbbVie (ABBV)?: Quarterly income statement (USD thousands); Revenue by segment; Reported versus estimated, last 8 quarters; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • 3. What are the financial strengths and risks for AbbVie (ABBV)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Quarterly income statement (USD thousands); Revenue by segment
  • 4. What should you watch next at AbbVie (ABBV)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Revenue by segment; Most recent periodic reports
  • 5. How does AbbVie compare with its peers?: Business description; Revenue by segment; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash against market value; Trailing twelve-month ratio set
  • FAQ: How dependent is AbbVie on Skyrizi and Rinvoq?: Revenue by segment; Business description; Annual revenue and net result (USD millions)
  • FAQ: What does Humira's smaller role mean for AbbVie?: Revenue by segment; Business description
  • FAQ: Why can AbbVie's research spending make earnings volatile?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
  • FAQ: Can Skyrizi-led cash generation support AbbVie's debt load?: Revenue by segment; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash against market value
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ABBV

Funds in our ETF coverage that list ABBV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
PBPH ETF6.33%
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)6.08%
VHT ETF6.00%
ProShares - Ultra Health Care (RXL)5.02%
IXJ ETF4.95%
WisdomTree U.S. High Dividend Fund (DHS)4.52%
Simplify Health Care ETF (PINK)4.50%
First Trust Bloomberg R&D Leaders ETF (RND)4.12%
BNY Mellon Women's Opportunities ETF (BKWO)3.02%
Xtrackers S&P 500 Value Scored & Screened ETF (SNPV)2.98%